{
    "root": "308e8bf5-b559-e8fa-e063-6394a90a03df",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Loxapine",
    "value": "20250317",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FD&C BLUE NO. 2--ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "FD&C BLUE NO. 1 ALUMINUM LAKE",
            "code": "J9EQA3S2JM"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "LOXAPINE SUCCINATE",
            "code": "X59SG0MRYU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6549"
        }
    ],
    "indications": {
        "text": "loxapine capsules indicated treatment schizophrenia . efficacy loxapine schizophrenia established enrolled newly hospitalized chronically hospitalized acutely ill schizophrenic patients subjects .",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "loxapine administered , usually divided doses , two four times day . daily ( terms base equivalents ) adjusted individual patient 's needs assessed severity symptoms previous history response antipsychotic drugs .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "loxapine capsules , usp available following strengths : loxapine succinate , usp 68.0 mg equivalent 50 mg loxapine , black ink , hard shell capsules size 2 , opaque , light blue cap dark green body imprinted `` e528 `` cap body , supplied ndc : 70518-4311-00 packaging : 30 1 blister pack store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense tight container defined usp , child-resistant closure , required . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "loxapine contraindicated comatose severe drug-induced depressed states ( alcohol , barbiturates , narcotics , etc . ) . loxapine contraindicated individuals known hypersensitivity dibenzoxazepines .",
    "indications_original": "Loxapine capsules are indicated for the treatment of schizophrenia. The efficacy of loxapine in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects.",
    "contraindications_original": "Loxapine is administered, usually in divided doses, two to four times a day. Daily dosage (in terms of base equivalents) should be adjusted to the individual patient's needs as assessed by the severity of symptoms and previous history of response to antipsychotic drugs.",
    "warningsAndPrecautions_original": "Loxapine Capsules, USP are available in the following strengths:\n                  Loxapine succinate, USP 68.0 mg equivalent to 50 mg loxapine,black ink, hard shell capsules Size 2, opaque, with light blue cap and dark green body imprinted with \"E528\" on cap and body, are supplied in\n                  NDC: 70518-4311-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Dispense in a tight\u00a0container as defined in the USP, with a child-resistant closure, as required.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Loxapine is contraindicated in comatose or severe drug-induced depressed states (alcohol, barbiturates, narcotics, etc.). \n  \n                       Loxapine is contraindicated in individuals with known hypersensitivity to dibenzoxazepines.",
    "drug": [
        {
            "name": "Loxapine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50841"
        }
    ]
}